Buy & Sell Amazon.com Inc (AMZN) – Amazon.com Inc Price Today
Aura AI Summary
Key Stats
- $2.63TMarket Cap
- Consumer CyclicalSector
- -11.19%3M Drawdown
- $2.69TEnterprise Value
- -Dividend Yield
- 50% Buy | 50% SellTrading Activity
- 119 daysTypical Hold Time
Amazon.com Inc (AMZN) is currently valued at a market capitalization of $2.63T, with an enterprise value of $2.69T. Over the past 52 weeks, Amazon.com Inc has traded between a low of $198.79 and a high of $274.95, highlighting its annual price range. Over the past three months, Amazon.com Inc has recorded a drawdown of -11.19%, reflecting recent price volatility. On average, investors hold Amazon.com Inc for approximately 119 days, indicating typical investor behavior on the platform.
About Amazon.com Inc
Amazon.com, Inc. is an online retailer that offers a wide range of products. The Company products include books, music, computers, electronics and numerous other products. Amazon offers personalized shopping services, Web-based credit card payment, and direct shipping to customers. Amazon also operates a cloud platform offering services globally.
Most Recent News
Global Initiative on Loneliness and Connection hosts forum to tackle social division and loneliness worldwide
The Global Initiative on Loneliness and Connection (GILC) convened the 2026 Global Connection Forum on June 17 to address the growing public health crisis of loneliness and social isolation, which contribute to serious health risks and societal divis...

Metastatic prostate cancer market to grow strongly through 2036 with new targeted therapies emerging.
The metastatic prostate cancer market is shifting from traditional hormone therapies to precision, biomarker-driven treatments, including novel PARP inhibitors and PSMA-targeted radioligand therapies. The market, valued at $11.5 billion in 2025 in ma...

Over 30 pharma companies race to develop 35+ lupus nephritis drugs, advancing treatment options globally.
The lupus nephritis clinical trial landscape is rapidly expanding with more than 30 pharmaceutical companies developing over 35 drugs targeting this serious autoimmune kidney condition. Key players like Novartis, Simcere, and Regeneron are advancing ...
